Here are three things to know about the expanded relationships.
1. Through individual agreements, Celgene and Amgen will collaborate with Flatiron Health to accelerate clinical research, advance personalized medicine and enhance treatment options for cancer patients. Additionally, Celgene Switzerland and Amgen Ventures have invested in Flatiron Health’s recently announced fundraising round.
2. Celgene will work with Flatiron Health to further shape its offering, which uses longitudinal real-world data at scale as an alternative to traditional prospective registries, according to a news release. Separately, Flatiron Health and Celgene will continue providing patient access tools at the point of care within Flatiron Health’s OncologyCloudsoftware platform.
3. Additionally, Flatiron Health will continue supporting Amgen’s customized resource of real-world oncology data: Oncology Services Comprehensive Electronic Records, the parties said. OSCER allows researchers to conduct observational studies and publish insights on cancer care. Amgen also will leverage Flatiron Health’s products that integrate de-identified clinical treatment and outcomes data with genomic profiling data “to accelerate clinical research efforts and inform the development of novel targeted therapies,” the parties said.
More articles on health IT:
Google, Kivney to launch HIPAA-compliant mobile service on Google Cloud
mHealth market to experience rapid growth through 2022
The rise of mHelath: 157M users by 2020
